Cost Effectiveness of Free Access to Smoking Cessation Treatment in France Considering the Economic Burden of Smoking-Related Diseases
Open Access
- 24 February 2016
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 11 (2), e0148750
- https://doi.org/10.1371/journal.pone.0148750
Abstract
In France more than 70,000 deaths from diseases related to smoking are recorded each year, and since 2005 prevalence of tobacco has increased. Providing free access to smoking cessation treatment would reduce this burden. The aim of our study was to estimate the incremental cost-effectiveness ratios (ICER) of providing free access to cessation treatment taking into account the cost offsets associated with the reduction of the three main diseases related to smoking: lung cancer, chronic obstructive pulmonary disease (COPD) and cardiovascular disease (CVD). To measure the financial impact of such a measure we also conducted a probabilistic budget impact analysis. We performed a cost-effectiveness analysis using a Markov state-transition model that compared free access to cessation treatment to the existing coverage of €50 provided by the French statutory health insurance, taking into account the cost offsets among current French smokers aged 15–75 years. Our results were expressed by the incremental cost-effectiveness ratio in 2009 Euros per life year gained (LYG) at the lifetime horizon. We estimated a base case scenario and carried out a Monte Carlo sensitivity analysis to account for uncertainty. Assuming a participation rate of 7.3%, the ICER value for free access to cessation treatment was €3,868 per LYG in the base case. The variation of parameters provided a range of ICER values from -€736 to €15,715 per LYG. In 99% of cases, the ICER for full coverage was lower than €11,187 per LYG. The probabilistic budget impact analysis showed that the potential cost saving for lung cancer, COPD and CVD ranges from €15 million to €215 million at the five-year horizon for an initial cessation treatment cost of €125 million to €421 million. The results suggest that providing medical support to smokers in their attempts to quit is very cost-effective and may even result in cost savings.This publication has 30 references indexed in Scilit:
- Cost effectiveness of full coverage of the medical management of smoking cessation in FranceTobacco Control, 2012
- A Lifetime Markov Model for the Economic Evaluation of Chronic Obstructive Pulmonary DiseasePharmacoEconomics, 2012
- Simulation-Based Estimates of Effectiveness and Cost-Effectiveness of Smoking Cessation in Patients with Chronic Obstructive Pulmonary DiseasePLOS ONE, 2011
- The impact of the United Kingdom's national smoking cessation strategy on quit attempts and use of cessation services: Findings from the International Tobacco Control Four Country SurveyNicotine & Tobacco Research, 2010
- Estimating the cost of smoking to the NHS in England and the impact of declining prevalenceHealth Economics, Policy and Law, 2010
- Life expectancy and years of life lost in chronic obstructive pulmonary disease: Findings from the NHANES III Follow-up StudyInternational Journal of Chronic Obstructive Pulmonary Disease, 2009
- Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trialsCMAJ : Canadian Medical Association Journal, 2008
- The NICE Cost-Effectiveness ThresholdPharmacoEconomics, 2008
- Costs and benefits of smoking cessation aids: making a case for public reimbursement of nicotine replacement therapy in AustraliaTobacco Control, 2007
- Ten-Year Prognosis of Stroke and Risk Factors for Death in a Japanese CommunityStroke, 2003